Breaking News
Get 40% Off 0
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks. Unlock full list
Close

Sapporo Clinical Laboratory Inc (9776)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
996.0 0.0    0.00%
23/05 - Closed. Currency in JPY ( Disclaimer )
  • Volume: 2,400
  • Bid/Ask: 993.0 / 996.0
  • Day's Range: 992.0 - 996.0
Type:  Equity
Market:  Japan
ISIN:  JP3321100004 
Sapporo Clinical Laboratory 996.0 0.0 0.00%

9776 Balance Sheet

 
Featured here, the Balance Sheet for Sapporo Clinical Laboratory Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
Advanced Balance Sheet
Period Ending: 2024
31/03
2023
31/12
2023
30/09
2023
30/06
Total Current Assets 7696 7879 7707 7517
Cash and Short Term Investments 3976 3986 4065 3809
Cash - - - -
Cash & Equivalents 3976 3986 4065 3809
Short Term Investments - - - -
Total Receivables, Net 2919 2953 2944 2882
Accounts Receivables - Trade, Net 2919 2953 2944 2882
Total Inventory - 731 555 693
Prepaid Expenses - - - -
Other Current Assets, Total 223 209 143 133
Total Assets 16680 16935 16712 16656
Property/Plant/Equipment, Total - Net - 8297 8237 8373
Property/Plant/Equipment, Total - Gross - - - -
Accumulated Depreciation, Total - - - -
Goodwill, Net - - - -
Intangibles, Net - 98 98 87
Long Term Investments 554 517 528 532
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 1 3 2 1
Other Assets, Total -1976 -1872 -2106 -1910
Total Current Liabilities 3307 3590 3398 3515
Accounts Payable 2235 2543 2207 2609
Payable/Accrued - - - -
Accrued Expenses - 31 254 66
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 260 260 258 258
Other Current liabilities, Total 688 756 679 582
Total Liabilities 5499 5835 5689 5869
Total Long Term Debt 1936 1994 2039 2103
Long Term Debt 1464 1498 1531 1565
Capital Lease Obligations - 496 508 538
Deferred Income Tax 11 9 11 14
Minority Interest 246 256 263 267
Other Liabilities, Total -1 -14 -1689.15 -1728.9
Total Equity 11181 11100 11023 10787
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 983 983 983 983
Additional Paid-In Capital - 1015 1015 1015
Retained Earnings (Accumulated Deficit) 9607 9539 9453 9233
Treasury Stock - Common - -757 -757 -757
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 333 320 329 313
Total Liabilities & Shareholders' Equity - 16935 16712 16656
Total Common Shares Outstanding 3.33 3.33 3.33 3.33
Total Preferred Shares Outstanding - - - -
* In Millions of JPY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

9776 Comments

Write your thoughts about Sapporo Clinical Laboratory Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email